Integrated Filing — IndAS



General information about company

Scrip Code 544172
NSE Symbol INDGN
MSEI Symbol NOTLISTED
ISIN INE065X01017
Name of company Indegene Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 29-10-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 30-09-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Where financial results contain both consolidated financial results and standalone financial results of the parent, segment information is required to be presented only in the consolidated financial results. Accordingly, segment information has been presented in the consolidated financial results.
Start date and time of board meeting 29-10-2026   18:30:00
End date and time of board meeting 29-10-2026   19:16:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 29-04-2026
Indicate Company website link for updated RPT policy of the Company https://www.indegene.com
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
No external loans and debt securities held by Company



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 36,850.00 70,920.00
Other income 2,300.00 5,690.00
Total income 39,150.00 76,610.00
2 Expenses
(a) Cost of materials consumed 0.00 0.00
(b) Purchases of stock-in-trade 0.00 0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 0.00 0.00
(d) Employee benefit expense 23,480.00 45,650.00
(e) Finance costs 340.00 610.00
(f) Depreciation, depletion and amortisation expense 1,310.00 2,450.00
(f) Other Expenses
1 Other Expenses 6,190.00 12,070.00
Total other expenses 6,190.00 12,070.00
Total expenses 31,320.00 60,780.00
3 Total profit before exceptional items and tax 7,830.00 15,830.00
4 Exceptional items 0.00 0.00
5 Total profit before tax 7,830.00 15,830.00
6 Tax expense
7 Current tax 2,110.00 3,890.00
8 Deferred tax (100.00) 130.00
9 Total tax expenses 2,010.00 4,020.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 5,820.00 11,810.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 5,820.00 11,810.00
17 Other comprehensive income net of taxes (130.00) (50.00)
18 Total Comprehensive Income for the period 5,690.00 11,760.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 4,810.00 4,810.00
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 2.42 4.91
Diluted earnings (loss) per share from continuing operations 2.4 4.88
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 2.42 4.91
Diluted earnings (loss) per share from continuing and discontinued operations 2.4 4.88
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) Notes to the Statement of Standalone Financial Results for quarter and six months ended 30 September 2026 All amounts in INR millions except share data and where otherwise stated 3 The Standalone Financial Results for the quarter and six months ended 30 September 2026 are available on the National Stock Exchange of India Limited URL www nseindia com the BSE Limited website URL www bseindia com and on the Companys website URL www indegene com investor relations 5 The shareholders approved a final dividend of INR 2 and 25 paise per equity share for the financial year ended 31 March 2026 at the 28th Annual General Meeting held on 13 August 2026 The dividend was paid on 21 August 2026 resulting in a cash outflow of INR 542



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 15,030.00
Capital work-in-progress 0.00
Investment property 0.00
Goodwill 0.00
Other intangible assets 0.00
Intangible assets under development 0.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 61,660.00
Trade receivables, non-current 0.00
Loans, non-current 31,690.00
Other non-current financial assets
1 Other financial assets 1,500.00
Total of other non-current financial assets 1,500.00
Total non-current financial assets 94,850.00
Deferred tax assets (net) 2,260.00
Other non-current assets
1 Non-current tax assets (net) 370.00
2 Other non-current assets 90.00
Total of other non-current assets 460.00
Total non-current assets 1,12,600.00
2 Current assets
Inventories 0.00
Current financial asset
Current investments 73,870.00
Trade receivables, current 25,770.00
Cash and cash equivalents 1,290.00
Bank balance other than cash and cash equivalents 9,550.00
Loans, current 4,530.00
Other current financial assets
Total of other current financial assets 16,650.00
Total current financial assets 1,31,660.00
Current tax assets (net) 0.00
Other current assets
1 Other current assets 9,230.00
Total of other current assets 9,230.00
Total current assets 1,40,890.00
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 2,53,490.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 4,810.00
Other equity 2,10,940.00
Total equity attributable to owners of parent 2,15,750.00
Non controlling interest
Total equity 2,15,750.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Lease Liabilities 6,450.00
2 Other financial liabilities 310.00
Total of other non-current financial liabilities 6,760.00
Total non-current financial liabilities 6,760.00
Provisions, non-current 6,920.00
Deferred tax liabilities (net) 0.00
Deferred government grants, Non-current 0.00
Other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities 13,680.00
Current liabilities
Current financial liabilities
Borrowings, current 0.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 540.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 3,320.00
Total Trade payable 3,860.00
Other current financial liabilities
1 Lease liabilities 2,210.00
2 Other financial liabilities 9,140.00
Total of other current financial liabilities 11,350.00
Total current financial liabilities 15,210.00
Other current liabilities 2,260.00
1 Other current liabilities 2,260.00
Total of other current liabilities 2,260.00
Provisions, current 5,580.00
Current tax liabilities (Net) 1,010.00
Deferred government grants, Current 0.00
Total current liabilities 24,060.00
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 37,740.00
Total equity and liabilites 2,53,490.00
Disclosure of notes on assets and liabilities Textual Information(1)



Text Block

Textual Information(1) Notes to the Statement of Standalone Financial Results for quarter and six months ended 30 September 2026 All amounts in INR millions except share data and where otherwise stated 1 The above Standalone Financial Results of the Indegene Limited the Company have been prepared in accordance with Indian Accounting Standards Ind AS 34 Interim Financial Reporting recognition and measurement principles of Indian Accounting Standards Ind AS prescribed under Section 133 of the Companies Act 2013 as amended read with the relevant rules issued there under and in terms of Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations 2015 the Regulations Due to rounding off the numbers presented throughout may not add up precisely to the totals Caret symbol in the financial information denote amounts less than INR 5 lakhs 2 The above Standalone Financial Results have been reviewed by the Audit Committee held on 28 October 2026 and approved by the Board of Directors at its meeting held on 29 October 2026 The statutory auditors have performed a limited review of the Standalone Financial Results for the quarter and six months ended 30 September 2026 and have issued an unmodified review report on the same



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments Textual Information(2)



Text Block

Textual Information(2) 4 The Company publishes this Standalone Financial Results along with the Consolidated Financial Results In accordance with Ind AS 108 Operating Segments the Company has disclosed the segment information in the Consolidated Financial Results



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurement of defined benefit obligation 520.00 230.00
Total Amount of items that will not be reclassified to profit and loss 520.00 230.00
2 Income tax relating to items that will not be reclassified to profit or loss 130.00 60.00
3 Amount of items that will be reclassified to profit and loss
1 Net change in fair value of forward contracts designated as cash flow hedges (690.00) (290.00)
Total Amount of items that will be reclassified to profit and loss (690.00) (290.00)
4 Income tax relating to items that will be reclassified to profit or loss (170.00) (70.00)
5 Total Other comprehensive income (130.00) (50.00)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 15,830.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 570.00
Adjustments for decrease (increase) in inventories 0.00
Adjustments for decrease (increase) in trade receivables, current 2,620.00
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (100.00)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 40.00
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 0.00
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 2,450.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 560.00
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (2,740.00)
Adjustments for dividend income 0.00
Adjustments for interest income 2,450.00
Adjustments for share-based payments 320.00
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items (2,390.00)
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (1,120.00)
Net cash flows from (used in) operations 14,710.00
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 4,630.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 10,080.00
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 0.00
Purchase of property, plant and equipment 2,050.00
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 4,050.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 2,110.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (10,900.00)
Net cash flows from (used in) investing activities (6,790.00)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 90.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 0.00
Repayments of borrowings 0.00
Payments of lease liabilities 1,380.00
Dividends paid 5,420.00
Interest paid 0.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (6,710.00)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (3,420.00)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents (140.00)
Net increase (decrease) in cash and cash equivalents (3,560.00)
Cash and cash equivalents cash flow statement at beginning of period 4,850.00
Cash and cash equivalents cash flow statement at end of period 1,290.00





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Unaudited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Deloitte Haskins & Sells Yes 30-04-2028


Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Indegene Limited Cult Health LLC Step Subsidiary Sale of goods or services 680.00 Approved 180.00 50.00 60.00
2 Indegene Limited DT Associates Research and Consulting Services Limited Step Subsidiary Sale of goods or services 820.00 Approved 400.00 280.00 200.00
3 Indegene Limited Indegene FarEast Pte. Ltd. Step Subsidiary Sale of goods or services 120.00 Approved 0.00 20.00 0.00
4 Indegene Limited Indegene Healthcare Canada, Inc. Step Subsidiary Sale of goods or services 90.00 Approved 20.00 0.00 10.00
5 Indegene Limited Indegene Ireland Limited Subsidiary Sale of goods or services 190.00 Approved 60.00 20.00 20.00
6 Indegene Limited Indegene Japan LLC Step Subsidiary Sale of goods or services 200.00 Approved 50.00 10.00 10.00
7 Indegene Limited Indegene Lifesystems Consulting (Shanghai) Co. Ltd. Step Subsidiary Sale of goods or services 570.00 Approved 130.00 150.00 150.00
8 Indegene Limited Indegene, Inc. Step Subsidiary Sale of goods or services 1,40,000.00 Approved 63,310.00 24,880.00 22,120.00
9 Indegene Limited Indegene Healthcare Germany GmbH Step Subsidiary Sale of goods or services 420.00 Approved 90.00 10.00 20.00
10 Indegene Limited Trilogy Writing & Consulting Inc Step Subsidiary Sale of goods or services 90.00 Approved 30.00 10.00 10.00
11 Indegene Limited Biopharm Communications, LLC Step Subsidiary Sale of goods or services 90.00 Approved 40.00 0.00 10.00
12 Indegene Limited Addressable Health LLC Step Subsidiary Sale of goods or services 90.00 Approved 10.00 0.00 0.00
13 Indegene, Inc. Cult Health LLC Fellow Subisidary Sale of goods or services 0.00 Not applicable 160.00 20.00 40.00
14 Indegene, Inc. DT Associates Research and Consulting Services Inc Fellow Subisidary Sale of goods or services 0.00 Not applicable 390.00 480.00 890.00
15 Indegene, Inc. DT Associates Research and Consulting Services Limited Fellow Subisidary Sale of goods or services 0.00 Not applicable 1,030.00 30.00 1,040.00
16 Indegene, Inc. Indegene Ireland Limited Fellow Subisidary Sale of goods or services 0.00 Not applicable 10.00 0.00 0.00
17 Indegene, Inc. Trilogy Writing & Consulting Inc Fellow Subisidary Sale of goods or services 0.00 Not applicable 0.00 0.00 0.00
18 Indegene, Inc. Addressable Health LLC Fellow Subisidary Sale of goods or services 0.00 Not applicable 90.00 0.00 0.00
19 Indegene, Inc. Biopharm Communications, LLC Fellow Subisidary Sale of goods or services 0.00 Not applicable 20.00 0.00 10.00
20 Biopharm Communications, LLC Addressable Health LLC Fellow Subisidary Sale of goods or services 0.00 Not applicable 220.00 430.00 170.00
21 Biopharm Communications, LLC Indegene, Inc. Fellow Subisidary Sale of goods or services 0.00 Not applicable 510.00 0.00 140.00
22 Cult Health LLC Indegene, Inc. Fellow Subisidary Sale of goods or services 0.00 Not applicable 4,570.00 870.00 2,730.00
23 DT Associates Research and Consulting Services Inc DT Associates Research and Consulting Services Limited Fellow Subisidary Sale of goods or services 0.00 Not applicable 160.00 1,140.00 1,330.00
24 DT Associates Research and Consulting Services Inc Indegene, Inc. Fellow Subisidary Sale of goods or services 0.00 Not applicable 670.00 (930.00) (690.00)
25 DT Associates Research and Consulting Services Limited Indegene Healthcare UK Ltd Parent Company Sale of goods or services 0.00 Not applicable 10.00 0.00 20.00
26 DT Associates Research and Consulting Services Limited Indegene, Inc. Fellow Subisidary Sale of goods or services 0.00 Not applicable 3,310.00 600.00 1,300.00
27 DT Associates Research and Consulting Services Limited Indgene Ireland Limited Parent Company Sale of goods or services 0.00 Not applicable 700.00 0.00 510.00
28 Indegene Europe LLC Indegene, Inc. Fellow Subisidary Sale of goods or services 0.00 Not applicable 620.00 140.00 190.00
29 Indegene Europe LLC Indegene Ireland Limited Parent Company Sale of goods or services 0.00 Not applicable 40.00 0.00 40.00
30 Indegene FarEast Pte. Ltd. Indegene, Inc. Fellow Subisidary Sale of goods or services 0.00 Not applicable 210.00 30.00 110.00
31 Indegene Healthcare Canada, Inc. Indegene, Inc. Parent Company Sale of goods or services 0.00 Not applicable 2,340.00 1,820.00 2,440.00
32 Indegene Healthcare Canada, Inc. Indegene Ireland Limited Fellow Subisidary Sale of goods or services 0.00 Not applicable 0.00 0.00 0.00
33 Indegene Healthcare Canada, Inc. Indegene Healthcare Germany GmbH Fellow Subisidary Sale of goods or services 0.00 Not applicable 560.00 860.00 110.00
34 Indegene Healthcare Canada, Inc. Trilogy Writing & Consulting Inc Fellow Subisidary Sale of goods or services 0.00 Not applicable 320.00 10.00 60.00
35 Indegene Healthcare Germany GmbH Indegene, Inc. Fellow Subisidary Sale of goods or services 0.00 Not applicable 2,260.00 300.00 710.00
36 Indegene Healthcare UK Ltd Indegene Limited Ultimate Parent Company Sale of goods or services 0.00 Not applicable 300.00 90.00 0.00
37 Indegene Healthcare UK Ltd Indegene, Inc. Fellow Subisidary Sale of goods or services 0.00 Not applicable 4,600.00 620.00 1,670.00
38 Indegene Healthcare UK Ltd DT Associates Research and Consulting Services Limited Subsidiary Sale of goods or services 0.00 Not applicable 180.00 0.00 220.00
39 Indegene Healthcare UK Ltd Indegene Healthcare Germany GmbH Fellow Subisidary Sale of goods or services 0.00 Not applicable 1,060.00 0.00 180.00
40 Indegene Healthcare UK Ltd Trilogy Writing & Consulting Inc Fellow Subisidary Sale of goods or services 0.00 Not applicable 730.00 0.00 1,530.00
41 Indegene Healthcare UK Ltd Warn & Co Limited Fellow Subisidary Sale of goods or services 0.00 Not applicable 520.00 0.00 0.00
42 Indegene Healthcare UK Ltd Indegene Ireland Limited Parent Company Sale of goods or services 0.00 Not applicable 80.00 0.00 20.00
43 Indegene Ireland Limited Indegene, Inc. Fellow Subisidary Sale of goods or services 0.00 Not applicable 400.00 130.00 110.00
44 Indegene Ireland Limited Indegene Limited Parent Company Sale of goods or services 0.00 Not applicable 50.00 0.00 0.00
45 Indegene Japan LLC Indegene, Inc. Fellow Subisidary Sale of goods or services 0.00 Not applicable 270.00 0.00 90.00
46 Indegene Lifesystems Consulting (Shanghai) Co. Ltd. Indegene, Inc. Fellow Subisidary Sale of goods or services 0.00 Not applicable 770.00 0.00 0.00
47 Indegene Spain SL DT Associates Research and Consulting Services Limited Fellow Subisidary Sale of goods or services 0.00 Not applicable 180.00 40.00 130.00
48 Indegene Spain SL Indegene Limited Ultimate Parent Company Sale of goods or services 0.00 Not applicable 180.00 10.00 40.00
49 Indegene Spain SL Indegene, Inc. Fellow Subisidary Sale of goods or services 0.00 Not applicable 490.00 40.00 90.00
50 Indegene Spain SL Indegene Ireland Limited Parent Company Sale of goods or services 0.00 Not applicable 0.00 0.00 0.00
51 MJL Advertising Limited Indegene, Inc. Fellow Subisidary Sale of goods or services 0.00 Not applicable 140.00 70.00 80.00
52 Indegene Healthcare Germany GmbH Trilogy Writing & Consulting Inc Subsidiary Sale of goods or services 0.00 Not applicable 820.00 6,070.00 2,290.00
53 Indegene Healthcare Germany GmbH Indegene Limited Ultimate Parent Company Sale of goods or services 0.00 Not applicable 50.00 0.00 10.00
54 Indegene Healthcare Germany GmbH Indegene Ireland Limited Parent Company Sale of goods or services 0.00 Not applicable 40.00 0.00 30.00
55 Indegene Healthcare Germany GmbH Cake Kommunikations GmbH - Austria Fellow Subisidary Sale of goods or services 0.00 Not applicable 0.00 0.00 0.00
56 Trilogy Writing & Consulting Inc Indegene Healthcare Germany GmbH Parent Company Sale of goods or services 0.00 Not applicable 1,030.00 8,370.00 5,060.00
57 Trilogy Writing & Consulting Inc Indegene Healthcare UK Ltd Fellow Subisidary Sale of goods or services 0.00 Not applicable 0.00 0.00 150.00
58 Trilogy Writing & Consulting Limited Indegene Healthcare Germany GmbH Fellow Subisidary Sale of goods or services 0.00 Not applicable 0.00 (850.00) 0.00
59 Trilogy Writing & Consulting Limited Trilogy Writing & Consulting Inc Fellow Subisidary Sale of goods or services 0.00 Not applicable 0.00 1,980.00 (60.00)
60 Trilogy Writing & Consulting Limited Indegene Healthcare UK Ltd Parent Company Sale of goods or services 0.00 Not applicable 110.00 0.00 140.00
61 Warn & Co Limited Indegene, Inc. Fellow Subisidary Sale of goods or services 0.00 Not applicable 0.00 30.00 0.00
62 Cult Health LLC MJL Advertising Limited Fellow Subisidary Sale of goods or services 0.00 Not applicable 30.00 0.00 0.00
63 Indegene Healthcare Mexico S DE RL DE CV Indegene, Inc. Fellow Subisidary Sale of goods or services 0.00 Not applicable 40.00 0.00 0.00
64 Cake Kommunikations GmbH - Austria Indegene, Inc. Fellow Subisidary Sale of goods or services 0.00 Not applicable 20.00 0.00 0.00
65 Cake Kommunikations GmbH - Austria Cake Kommunikations AG Fellow Subisidary Sale of goods or services 0.00 Not applicable 100.00 0.00 0.00
66 Cake Kommunikations GmbH - Germany Indegene, Inc. Fellow Subisidary Sale of goods or services 0.00 Not applicable 150.00 0.00 0.00
67 Cake Kommunikations GmbH - Germany Cake Kommunikations GmbH - Austria Fellow Subisidary Sale of goods or services 0.00 Not applicable 50.00 0.00 0.00
68 Indegene, Inc. Indegene Lifesystems Consulting (Shanghai) Co. Ltd. Fellow Subisidary Sale of goods or services 0.00 Not applicable 0.00 570.00 580.00
69 Addressable Health LLC ILSL Holdings, Inc. Parent Company Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 120.00 0.00 0.00
70 Biopharm Communications, LLC Addressable Health LLC Fellow Subisidary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 0.00 0.00 0.00
71 Biopharm Communications, LLC ILSL Holdings, Inc. Parent Company Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 330.00 0.00 0.00
72 Biopharm Communications, LLC Indegene, Inc. Fellow Subisidary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 0.00 0.00 0.00
73 Cake Kommunikations GmbH - Austria Cake Kommunikations GmbH - Germany Fellow Subisidary Any other transaction Advance given 0.00 Not applicable 10.00 0.00 0.00
74 Cake Kommunikations GmbH - Austria Cake Kommunikations GmbH - Germany Fellow Subisidary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 0.00 0.00 0.00
75 Cake Kommunikations GmbH - Austria Cake Kommunikations Holdings GmbH Parent Company Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 0.00 0.00 0.00
76 Cult Health LLC Indegene, Inc. Fellow Subisidary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 0.00 (290.00) 0.00
77 Cult Health LLC MJL Advertising Limited Fellow Subisidary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 0.00 0.00 0.00
78 Cult Health LLC Trilogy Writing & Consulting Inc Fellow Subisidary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 0.00 0.00 0.00
79 DT Associates Research and Consulting Services Inc DT Associates Research and Consulting Services Limited Fellow Subisidary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 0.00 10.00 10.00
80 DT Associates Research and Consulting Services Inc Indegene, Inc. Fellow Subisidary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 20.00 10.00 10.00
81 DT Associates Research and Consulting Services Limited Indegene, Inc. Fellow Subisidary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 130.00 440.00 10.00
82 DT Associates Research and Consulting Services Limited Warn & Co Limited Fellow Subisidary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 0.00 0.00 0.00
83 DT Associates Research and Consulting Services Limited DT Associates Research and Consulting Services Inc Fellow Subisidary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 0.00 10.00 0.00
84 ILSL Holdings, Inc. Biopharm Communications, LLC Step Subsidiary Any other transaction Rental income 0.00 Not applicable 100.00 0.00 40.00
85 Indegene Healthcare Canada, Inc. Indegene, Inc. Parent Company Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 10.00 40.00 0.00
86 Indegene Healthcare Germany GmbH Indegene Limited Ultimate Parent Company Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 0.00 10.00 0.00
87 Indegene Healthcare Germany GmbH Trilogy Writing & Consulting Limited Fellow Subisidary Loan 0.00 Not applicable 0.00 680.00 0.00 Loan 15.00 20 years Unsecured Business needs
88 Indegene Healthcare Germany GmbH Indegene Healthcare UK Ltd Fellow Subisidary Loan 0.00 Not applicable 0.00 0.00 220.00 Loan 15.00 20 years Unsecured Business needs
89 Indegene Healthcare Germany GmbH Trilogy Writing & Consulting Limited Fellow Subisidary Interest received 0.00 Not applicable 0.00 0.00 0.00
90 Indegene Healthcare Germany GmbH Trilogy Writing & Consulting Inc Subsidiary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 0.00 0.00 0.00
91 Indegene Healthcare UK Ltd DT Associates Research and Consulting Services Limited Subsidiary Any other transaction Rental income 0.00 Not applicable 210.00 40.00 290.00
92 Indegene Healthcare UK Ltd Indegene, Inc. Fellow Subisidary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 0.00 500.00 0.00
93 Indegene Healthcare UK Ltd DT Associates Research and Consulting Services Limited Subsidiary Any other transaction Advance given 0.00 Not applicable 730.00 370.00 90.00
94 Indegene Ireland Limited Indegene Spain SL Subsidiary Any other transaction Advance given 0.00 Not applicable 0.00 110.00 110.00
95 Indegene Ireland Limited MJL Advertising Limited Subsidiary Any other transaction Advance given 0.00 Not applicable 40.00 0.00 40.00
96 Indegene Ireland Limited Indegene Healthcare UK Ltd Subsidiary Any other transaction Advance given 0.00 Not applicable 380.00 0.00 380.00
97 Indegene Japan LLC DT Associates Research and Consulting Services Limited Fellow Subisidary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 0.00 0.00 0.00
98 Indegene Limited Cult Health LLC Step Subsidiary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 120.00 20.00 20.00
99 Indegene Limited DT Associates Research and Consulting Services Limited Step Subsidiary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable (120.00) 1,250.00 1,150.00
100 Indegene Limited Indegene Fareast Pte Ltd. Step Subsidiary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 10.00 0.00 0.00
101 Indegene Limited Indegene Healthcare Germany GmbH Step Subsidiary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 50.00 20.00 20.00
102 Indegene Limited Indegene Healthcare UK Ltd Step Subsidiary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 170.00 30.00 20.00
103 Indegene Limited Indegene, Inc. Step Subsidiary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 990.00 320.00 520.00
104 Indegene Limited Trilogy Writing & Consulting Limited Step Subsidiary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 0.00 20.00 0.00
105 Indegene Limited Indegene Europe LLC Step Subsidiary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable (20.00) 0.00 (20.00)
106 Indegene Limited Indegene Healthcare Canada, Inc. Step Subsidiary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable (10.00) 0.00 (10.00)
107 Indegene Limited Indegene Ireland Limited Subsidiary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 10.00 0.00 10.00
108 Indegene Limited Indegene Japan LLC Step Subsidiary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 0.00 0.00 0.00
109 Indegene Limited ILSL Holdings, Inc. Subsidiary Interest received 4,300.00 Approved 1,770.00 930.00 860.00
110 Indegene Limited Indegene Lifesystems Consulting (Shanghai) Co. Ltd. Step Subsidiary Interest received 90.00 Approved 50.00 30.00 0.00
111 Indegene Limited ILSL Holdings, Inc. Subsidiary Loan 860.00 Approved 4,130.00 39,870.00 36,220.00 Loan 9.0400 5 years Unsecured Repayment/prepayment of the term loan from bank Textual Information(1)
112 Indegene Limited Indegene Lifesystems Consulting (Shanghai) Co. Ltd. Step Subsidiary Loan 0.00 Not applicable 90.00 70.00 0.00 Loan 8.00 5 and 10 years Unsecured Business needs
113 Indegene Limited Dr. Ashish Gupta Non- executive Independent Director Any other transaction Commission 100.00 Approved 50.00 0.00 0.00
114 Indegene Limited Mr. Jairaj Manohar Purandare Non- executive Independent Director Any other transaction Commission 50.00 Approved 30.00 0.00 0.00
115 Indegene Limited Mr. Pravin Udhyavara Bhadya Rao Non- executive Independent Director Any other transaction Commission 50.00 Approved 30.00 0.00 0.00
116 Indegene Limited Mr. Krishnamurthy Venugopala Tenneti Non- executive Independent Director Any other transaction Commission 50.00 Approved 30.00 0.00 0.00
117 Indegene Limited Dr. Georgia Nikolakopoulou Papathomas Non- executive Independent Director Any other transaction Commission 100.00 Approved 50.00 0.00 0.00
118 Indegene Limited Jill DeSimone Non- executive Independent Director Any other transaction Commission 100.00 Approved 50.00 0.00 0.00
119 Indegene Limited Neeraj Bharadwaj Non- executive Independent Director Any other transaction Commission 100.00 Approved 50.00 0.00 0.00
120 Indegene Limited Manish Gupta Chief Executive Officer and Executive Director Remuneration 0.00 Not applicable 210.00 0.00 0.00
121 Indegene Limited Dr. Sanjay S Parikh Executive Director Remuneration 0.00 Not applicable 140.00 0.00 0.00
122 Indegene Limited Ms. Srishti Ramesh Kaushik Company Secretary Remuneration 0.00 Not applicable 30.00 0.00 0.00
123 Indegene Limited Suhas Prabhu Chief Financial Officer Remuneration 0.00 Not applicable 210.00 0.00 0.00
124 Indegene Limited Rajesh Bhaskaran Nair Non-Executive Director Remuneration 0.00 Not applicable 160.00 0.00 0.00
125 Indegene Spain SL Indegene Healthcare Germany GmbH Fellow Subisidary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 10.00 0.00 0.00
126 Indegene, Inc. Addressable Health LLC Fellow Subisidary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 60.00 30.00 0.00
127 Indegene, Inc. Biopharm Communications, LLC Fellow Subisidary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 310.00 30.00 20.00
128 Indegene, Inc. Cult Health LLC Fellow Subisidary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 340.00 130.00 10.00
129 Indegene, Inc. DT Associates Research and Consulting Services Limited Fellow Subisidary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 0.00 20.00 0.00
130 Indegene, Inc. DT Associates Research and Consulting Services Inc Fellow Subisidary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 0.00 0.00 510.00
131 Indegene, Inc. DT Associates Research and Consulting Services Limited Fellow Subisidary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 0.00 0.00 390.00
132 Indegene, Inc. Indegene Healthcare Canada, Inc. Subsidiary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 0.00 0.00 0.00
133 Indegene, Inc. Indegene Lifesystems Consulting (Shanghai) Co. Ltd. Fellow Subisidary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 70.00 1,460.00 1,560.00
134 Indegene, Inc. DT Associates Research and Consulting Services Inc Fellow Subisidary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 0.00 0.00 20.00
135 Indegene, Inc. Indegene Limited Ultimate Parent Company Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 10.00 20.00 0.00
136 Indegene, Inc. MJL Advertising Limited Fellow Subisidary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 0.00 10.00 0.00
137 Indegene, Inc. Trilogy Writing & Consulting Inc Fellow Subisidary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 530.00 210.00 200.00
138 ILSL Holdings, Inc. Indegene, Inc. Subsidiary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 110.00 0.00 40,010.00
139 Indegene, Inc. ILSL Holdings, Inc. Parent Company Any other transaction Advance given 0.00 Not applicable 2,380.00 0.00 45,080.00
140 Indegene, Inc. ILSL Holdings, Inc. Parent Company Any other transaction Advance given 0.00 Not applicable 20,620.00 1,33,560.00 1,55,520.00
141 Indegene, Inc. DT Associates Research and Consulting Services Limited Fellow Subisidary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 0.00 950.00 0.00
142 Indegene, Inc. Indegene Ireland Limited Fellow Subisidary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 10.00 0.00 0.00
143 Indegene, Inc. Indegene Healthcare Mexico S DE RL DE CV Fellow Subisidary Any other transaction Advance given 0.00 Not applicable 20.00 20.00 10.00
144 Indegene, Inc. Indegene Healthcare UK Ltd Fellow Subisidary Any other transaction Advance given 0.00 Not applicable 2,390.00 0.00 110.00
145 MJL Advertising Limited Indegene Ireland Limited Parent Company Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 100.00 0.00 0.00
146 Trilogy Writing & Consulting Inc Indegene Healthcare Canada, Inc. Fellow Subisidary Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 0.00 0.00 320.00
147 Trilogy Writing & Consulting Limited Indegene Healthcare UK Ltd Parent Company Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 10.00 0.00 10.00
148 Trilogy Writing & Consulting Limited Indegene Healthcare UK Ltd Parent Company Loan 0.00 Not applicable 200.00 0.00 160.00 Loan 1.2500 20 years Unsecured Business needs
149 Warn & Co Limited Indegene Ireland Limited Parent Company Any other transaction Expense paid on behalf of subsidiary 0.00 Not applicable 30.00 0.00 30.00
150 Indegene, Inc. Indegene Lifesystems Consulting (Shanghai) Co. Ltd. Fellow Subisidary Any other transaction Advance given 0.00 Not applicable 780.00 500.00 470.00
Total value of transaction during the reporting period 1,33,250.00



Text Block

Textual Information(1) Movement in on account of change in foreign exchange rate and Repayment of Loan